Site activation in neurology trials is the end-to-end process of completing all regulatory, contractual, operational, and training prerequisites required before a CNS clinical site can enroll its first participant – a process that differs from activation in other therapeutic areas because of CNS-specific prerequisites including rater certification, biomarker screening infrastructure qualification, and caregiver consent workflow approval that must complete before a site can be considered genuinely ready to enroll.

According to a June 2025 survey of more than 100 principal investigators and senior site personnel, 55% of sites report the time from site selection to full activation now exceeds five months, 39% report timelines are longer than two years ago, and 66% say contract and budget delays occur frequently. At an average direct Phase III trial cost of $55,716 per day (Tufts CSDD, 2024), a five-month activation delay is not an administrative inconvenience – it is a seven-figure operational exposure that compounds through the program’s enrollment window.

Site activation in a clinical trial is the process of completing all regulatory, contractual, operational, and training prerequisites that must be in place before a site can enroll its first participant. In a neurology program, this includes all standard milestones, contract execution, IRB approval, regulatory document collection, IMP shipment, staff training, and site initiation visit, plus CNS-specific prerequisites: rater certification for every staff member administering primary endpoint scales, biomarker screening infrastructure qualification (PET scanner or CSF protocol), pharmacy qualification for CNS compound storage, and caregiver or LAR consent workflow IRB approval.

According to a June 2025 industry survey, budget negotiations (cited by 72% of sites) and contract finalization (60%) are the top barriers to initiation, with 47% of sites rating sponsor and CRO communication as average or poor. In CNS-specific programs, these delays are compounded by rater credentialing timelines, imaging site qualification requirements, and the higher per-visit operational burden of neurology protocols that makes initial budget proposals systematically underestimate site costs.

The enrollment curve impact is non-linear because CNS sites activate pre-screening pipelines ahead of their expected enrollment start date. A memory center told to expect activation in month 4 begins referring pre-screen candidates from its patient registry in month 2 or 3. When activation slips to month 7, those pre-screened candidates have often progressed past the eligibility window, declined after waiting, or enrolled at a competing trial. Adding replacement sites does not recover this loss – each new site carries its own 5-month activation timeline and begins with no pre-screened patient pipeline.

The enrollment curve impact is non-linear because CNS sites activate pre-screening pipelines ahead of their expected enrollment start date. A memory center told to expect activation in month 4 begins referring pre-screen candidates from its patient registry in month 2 or 3. When activation slips to month 7, those pre-screened candidates have often progressed past the eligibility window, declined after waiting, or enrolled at a competing trial. Adding replacement sites does not recover this loss – each new site carries its own 5-month activation timeline and begins with no pre-screened patient pipeline.

“Sponsors often assume that site selection is the hardest part of a neurology program, find the right memory center, the right PI, and enrollment follows. What we see consistently is that the site selected on paper and the site ready to enroll are two very different things. We do a rigorous qualification review after activation specifically because projected patient counts at selection rarely survive first contact with actual screening capacity, staff turnover, and rater readiness.”

– Kyle Hanson, Director of Clinical Operations at Sitero

The industry standard target for end-to-end site startup is 90 to 120 days. According to ACRP (2025), actual median activation times at academic medical centers and hospitals run 140 to 167 days, with some sites exceeding 300 days when contract negotiations stall. For a neurology program running 80 to 100 global sites, the difference between a 90-day median and a 167-day median is the difference between hitting the first-patient-in milestone on the budgeted timeline and explaining a six-month enrollment delay before the study has started.

Rater credentialing for CNS assessment scales, ADAS-Cog, CDR, MDS-UPDRS, C-SSRS, must be completed and verified before a site can enroll its first participant, not initiated at the site initiation visit and completed while the site is nominally active. In a coordinated activation model, rater training is initiated before the SIV and certification completion is a verified prerequisite for the first-patient-in readiness check. A site that is marked activated on paper but whose raters are not yet certified is not activated for the purposes of the enrollment plan.

1. Has this site run a CNS protocol with a similar assessment battery in the last three years, and what was their median time from selection to first patient in on that program?
2. Does the site have sufficient rater-qualified staff to cover the planned enrollment rate, or will new staff need to be hired and trained before activation?
3. For programs with biomarker-based eligibility criteria, does the site have certified PET scanning access or CSF collection capability, and what is the lead time to qualify that infrastructure?
4. What is the site’s typical IRB review timeline for an industry-sponsored protocol, and does the IRB require a full-board review or is it eligible for expedited review?
5. Does the institution have pre-negotiated master clinical trial agreement (mCTA) language in place with your organization, or will each clause require institutional legal review?
6. What is the site’s caregiver or study partner enrollment process for programs requiring a legally authorized representative, and does the site have IRB-approved language for that workflow?
7. What is the estimated time from SIV scheduling to completion of rater certification for all planned assessment staff, and is that timeline built into the activation critical path or treated as a post-SIV activity?
8. Does the CRO have a CTMS milestone tracking system that provides real-time visibility into each site’s activation status, or will milestone tracking rely on CRA-updated spreadsheets?
9. What is the escalation process when a site’s activation milestone falls behind the critical path, who owns the intervention, and how quickly can contract or IRB issues be resolved?
10. For global programs, how are country-specific regulatory submission requirements, including the EU CTIS portal process under the 2025 CTR, mapped to the activation timeline before site selection is finalized?

Q1: What is site activation in a neurology clinical trial?

Site activation in a neurology clinical trial is the process of completing all regulatory, contractual, operational, and training prerequisites before a site can enroll its first participant. In a neurology program, this includes standard milestones, contract execution, IRB approval, regulatory documents, IMP shipment, and site initiation visit, plus CNS-specific prerequisites including rater certification for primary endpoint scale administrators, biomarker screening infrastructure qualification, pharmacy qualification for CNS compound storage, and caregiver or LAR consent workflow IRB approval. The industry standard target is 90 to 120 days; the actual median at academic medical centers runs 140 to 167 days.

Q2: What causes site activation delays in CNS clinical trials?

According to a June 2025 survey of more than 100 principal investigators and senior site personnel, budget negotiations (72% of sites) and contract finalization (60%) are the top barriers to site initiation in clinical trials. In CNS programs, these are compounded by rater credentialing timelines, imaging site qualification requirements for biomarker-based studies, and the higher per-visit operational burden of neurology protocols that causes initial budget proposals to systematically underestimate site costs. Communication gaps driven by fragmented milestone tracking are a third contributing factor, with 47% of sites in the survey rating sponsor and CRO communication as average or poor.

Q3: How much does a site activation delay cost a Phase 3 clinical trial?

According to Tufts CSDD’s 2024 analysis of 447 protocols, the mean direct cost to conduct a Phase III clinical trial is $55,716 per day. Each week a site is not activated represents approximately $390,000 in direct program costs, before accounting for the commercial value of lost sales time or the enrollment curve consequences of a delayed first patient in. For a neurology program running 80 to 100 global sites with a 5-month activation median, the aggregate delay cost across the site network is a material budget line item.

Q4: How does rater credentialing fit into the site activation timeline for a neurology trial?

Rater credentialing for CNS assessment scales must complete before a site can enroll its first participant, not after activation has been declared. In a coordinated activation model, rater training is initiated before the site initiation visit and certification completion is a verified prerequisite for the first-patient-in readiness check, not a step that runs concurrently with early enrollment. A site whose raters are not yet certified on the primary endpoint scales is not ready to enroll regardless of whether contract, IRB, and IMP milestones are complete.

Q5: What is the difference between site selection and site activation in a clinical trial?

Site selection is the process of identifying investigators with the patient access, staff capacity, and infrastructure to run a specific protocol. Site activation is completing all prerequisites before that site can enroll. The programs that consistently hit first-patient-in milestones treat them as overlapping: IRB preparation, contract language review, and rater training scheduling begin during feasibility, not after site selection is finalized. The 5-month activation median documented in the 2025 survey reflects the cost of treating them as sequential processes.

Sitero has supported more than 230 CNS, neurology, psychiatry, and behavioral health studies across 67 countries. Site activation in neurology programs is not a documentation workflow, it is a coordinated critical path with CNS-specific prerequisites that determine whether a program hits its first-patient-in milestone or spends its first year recovering from a startup gap.

Talk to a neurology trial expert to discuss your protocol, or use the button below to learn more on Sitero’s clinical operations capabilities:

1. CNS/Neurology Program Operational Data. Internal dataset. sitero.com/neurology/
2. Hanson K. Director of Clinical Operations, Sitero. Expert interview conducted for this article. September 2026.
3. Smith ZP, DiMasi JA, Getz KA. New Estimates on the Cost of a Delay Day in Drug Development. Ther Innov Regul Sci. 2024 Sep;58(5):855-862. doi: 10.1007/s43441-024-00667-w. Epub 2024 May 21. PMID: 38773058.
4. Overcoming study start-up delays: Best practices for research sites. ACRP. (2025, May 7). https://acrpnet.org/2025/05/07/overcoming-study-start-up-delays-best-practices-for-research-sites
5. IntuitionLabs. (2026, September 4). Clinical trial start-UP COSTS: A breakdown & benchmarks. IntuitionLabs. https://intuitionlabs.ai/articles/clinical-trial-start-up-costs
6. ICON plc. ICON Survey Reveals Increasing Clinical Trial Startup Delays. BusinessWire. December 2025. https://www.businesswire.com/news/home/20251202785702/en/ICON-Survey-Reveals-Increasing-Clinical-Trial-Startup-Delays
7. Getz K, Smith Z, Botto E, Murphy E, Dauchy A. New Benchmarks on Protocol Amendment Practices, Trends and their Impact on Clinical Trial Performance. Ther Innov Regul Sci. 2024 May;58(3):539-548. doi: 10.1007/s43441-024-00622-9. Epub 2024 Mar 4. PMID: 38438658.